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Abstract
Background: Chronic kidney disease (CKD) is a newly recognized high-risk condition for cardiovascular disease (CVD), 
and previous studies reported the changes in inflammation and oxidative stress in advanced stages of CKD. We 
compared the levels of serum biomarkers for inflammation and oxidative stress between subjects with normal and 
mildly reduced glomerular filtration rate (GFR).
Methods: The subjects were 182 participants of a health check-up program including those with normal (≥ 90 mL/
min/1.73 m2, N = 79) and mildly reduced eGFR (60-89 mL/min/1.73 m2, N = 103) which was calculated based on serum 
creatinine, age and sex. We excluded those with reduced eGFR < 60 mL/min/1.73 m2. No one had proteinuria. We 
measured serum levels of C-reactive protein (CRP) and thioredoxin (TRX) as the markers of inflammation and oxidative 
stress, respectively.
Results: As compared with subjects with normal eGFR, those with mildly reduced eGFR had increased levels of both 
CRP and TRX. Also, eGFR was inversely correlated with these biomarkers. The associations of eGFR with these 
biomarkers remained significant after adjustment for age and sex. When adjustment was done for eight possible 
confounders, CRP showed significant association with systolic blood pressure, high density lipoprotein cholesterol 
(HDL-C) and non-HDL-C, whereas TRX was associated with sex significantly, and with eGFR and systolic blood pressure 
at borderline significance.
Conclusions: We showed the increased levels of CRP and TRX in subjects with mildly reduced eGFR. The eGFR-CRP link 
and the eGFR-TRX link appeared to be mediated, at least partly, by the alterations in blood pressure and plasma lipids in 
these subjects.
Background
Chronic kidney disease (CKD) is a newly recognized
high-risk population for cardiovascular disease (CVD)
[1]. The relative risk of death from myocardial infarction
is 10-30 times higher in hemodialysis patients (CKD stage
5D) as compared to the general population [2]. Athero-
sclerotic vascular changes are present in patients with
CKD not yet treated with hemodialysis [3-5] as well as in
hemodialysis patients [6]. The risk for CVD increases in a
stepwise manner as glomerular filtration rate (GFR)
declines [7]. The increased risk of CVD in reduced GFR
may be explained at least partly by impairment of classi-
cal risk factors including hypertension [8], dyslipidemia
[9], and glucose intolerance/insulin resistance [10]. In
addition, inflammation and increased oxidative stress
[11,12] presumably contribute to the CKD-related excess
risk for CVD [1].
Oxidative stress is determined by the balance between
the production and elimination of reactive oxygen species
(ROS) [13]. Since superoxide anion and other ROS are dif-
ficult to be evaluated reliably in clinical conditions due to
their very short half-lives, more stable markers have been
measured in biological specimens. For example, oxidative
modifications of lipids, proteins, and nucleic acids can be
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evaluated by thiobarbituric acids-reactive substances
(TBARS)[14,15], advanced oxidation protein products
(AOPP), and 8-hydroxydeoxyguanodine (8-OHdG)[16],
respectively. In addition, proteins that are secreted into the
circulation in response to oxidative stress may serve as the
biomarkers for oxidative stress. Thioredoxin (TRX) is
among such proteins. TRX is a 12 kD protein, secreted by
most cell types, with a redox-active dithiol/disulfide in the
active site consensus sequence: -Cys-Gly-Pro-Cys-[17],
showing anti-oxidative properties. Plasma TRX levels are
increased in response to oxidative stress as shown in
experimental [18] and human studies [19-21]. Also, serum
TRX is known to be elevated in patients with increased
oxidative stress, such as pancreatic cancer [22], hepatitis C
virus infection [23], severe burn injury [24], acquired
immunodeficiency syndrome (AIDS) [25], rheumatoid
arthritis [26], heart failure [27], steato hepatitis [28], and
interstitial lung disease [29].
Uremia is considered as pro-oxidant state[11,30]. Previ-
ous studies demonstrated the elevated levels of biomark-
ers for oxidative modification of lipids[31] and
proteins[15] in dialysis patients, and in advanced stages of
CKD prior to renal replacement therapy[32]. So far, how-
ever, information is limited regarding possible changes in
inflammation and oxidative stress among subjects with
mild reduction of renal function[33-35].
In the present study, we measured C-reactive protein
(CRP) and TRX as biomarkers for inflammation and oxi-
dative stress, and compared them between subjects with
normal and mildly reduced glomerular filtration rate
(GFR).
Methods
Subjects
The subjects were recruited from 264 consecutive partic-
ipants of a health check-up program at the Osaka Health
Promotion Center, Osaka, Japan. Twenty-three individu-
als refused to participate, and 241 subjects gave written
informed consent to take part in the study. From the 241
people, we excluded 8 subjects with reduced eGFR < 60
mL/min/1.73 m2 and 51 subjects taking medications for
diabetes mellitus, hypertension, and/or dyslipidemia, to
avoid possible influence of these medications to oxidative
stress biomarkers. The remaining 182 individuals were
the final subjects of this study (Figure 1). Table 1 summa-
rizes the characteristics of the final subjects. No one had
proteinuria by a dip-stick method. According to the crite-
ria by the Kidney Disease Improving Global Outcomes
(KDIGO)[36], 79 subjects had normal eGFR (90 ml/min/
1.73 m2  or higher), and 103 subjects showed mildly
reduced eGFR (60-89 ml/min/1.73 m2). This study was
carried out in compliance with the Helsinki Declaration,
and approved by the ethics committee at Osaka City Uni-
versity Graduate School of Medical School.
Table 1: Characteristics of the subjects and summary of the 
measurements
Median (25th-75th 
percentile)
Age 53 (39--63)
Male sex (%) 38*
BMI (kg/m2) 22.3 (20.1--24.1)
Systolic BP (mmHg) 121 (108--133)
Diastolic BP (mmHg) 70 (63--76)
Non-HDL-cholesterol (mg/dl) 144 (118--168)
HDL-cholesterol (mg/dl) 60 (49--73)
Smokers (%) 38*
Fasting plasma glucose (mg/dl) 97 (92--102)
eGFR (ml/min/1.73 m2) 85 (76--96)
CRP (mg/dl) 0.04 (0.02--0.09)
TRX (ng/ml) 10.2 (7.9--12.4)
Values are medians (25th-75th percentile) for continuous 
variables, and percentage* for sex and smokers.
Abbreviations are: BMI, body mass index; BP, blood pressure; 
HOMA-IR, insulin resistance index by homeostasis model 
assessment; HDL, high density lipoprotein; Non-HDL; non high 
density lipoprotein; eGFR; estimated glomerular filtration rate; 
CRP, C-reactive protein; TRX, thioredoxin.
Figure 1 Recruitment and selection of the subjects. Abbreviations: 
DM, diabetes mellitus; HT, hypertension; DL, dyslipidemia.
Recruitment from 
participants of
health check-up
program (N=264)
Agreed to participate
(N=241)
Refused to 
participate (N=23)
Final study subjects 
(N=182)
Excluded because 
of medication for 
DM, HT and/or DL 
(N=51)
Excluded because
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Estimation of glomerular filtration rate
Glomerular filtration rate (GFR) was estimated by the fol-
lowing equation:
where Cr is serum creatinine level by an enzymatic
method. This equation was validated against the gold
standard inulin clearance methods among Japanese indi-
viduals [37].
Blood collection and measurements
Venous blood was collected after overnight fast into plas-
tic tubes. After clotting at room temperature for 10 min-
utes, the tubes were chilled in ice, and serum was
separated by centrifugation for 20 minutes at 4°C. Serum
levels of TRX were measured within 3 days after sampling
using frozen sera at -30°C. Other assays were performed
immediately. CRP was assayed by a sensitive Latex-
immunoassay (Denka Seiken, Tokyo) with a detection
limit of 0.01 mg/dL. Serum TRX was quantified using a
commercial ELISA kit for human TRX (Redox Bioscience
Inc, Kyoto) with a detection limit of 2 ng/mL. Serum cre-
atinine and total cholesterol was measured by enzymatic
methods. HDL-cholesterol were determined by homoge-
nous assays (Denka Seiken, Tokyo), and Non-HDL-cho-
lesterol was calculated by subtracting HDL-cholesterol
from total cholesterol. Body mass index (BMI) was calcu-
lated as body weight (kg) divided by squared height (m2).
Statistics
Because skewed distribution was found for CRP and TRX
in preliminary analyses, all continuous data were summa-
rized as median (25th-75th percentile levels). Categorical
d a t a  w e r e  g i v e n  i n  n u m b e r  o r  p e r c e n t a g e .  C o r r e l a t i o n
was evaluated by non-parametric Spearman's rank corre-
lation test. Difference in median levels between groups
was examined by Mann-Whitney's U-test. Multiple
r e g r e s s i o n  m o d e l s  w e r e  u s e d  t o  e v a l u a t e  i n d e p e n d e n t
associations, to which CRP and TRX were entered after
log-transformation to fit the linear models. P-values less
than 0.05 was taken to be statistically significant. All
these calculations were performed with StatView 5 soft-
ware (SAS Institute Inc., Cary, NC) for Windows per-
sonal computers.
Results
eGFR and CRP
Figure 2 shows the relationship between eGFR and CRP.
When compared between those with normal eGFR and
those with mildly reduced eGFR, the median CRP level
was significantly higher in the group with mildly reduced
eGFR. CRP was inversely correlated with eGFR in the
total subjects.
eGFR and TRX
Figure 3 shows the relationship between eGFR and TRX.
The median TRX level was significantly higher in the
group with reduced eGFR. TRX was inversely correlated
with eGFR in the total subjects.
Other factors correlating with CRP and TRX levels
We examined other factors that may affect the levels of
CRP and TRX (Table 2). CRP was positively correlated
with age, BMI, systolic BP, non-HDL-C levels, and glu-
cose levels, whereas CRP inversely correlated with HDL-
C. TRX was positively correlated with age, BMI, and sys-
tolic BP, and inversely with HDL-C. TRX showed no sig-
nificant correlation with plasma glucose or non-HDL-C.
CRP and TRX showed a significant positive correlation.
Correlations between eGFR and other clinical variables
As shown in Table 3, eGFR was significantly associated
with age, sex, BMI, systolic BP, non-HDL-C, HDL-C, and
smoking status, but not with glucose level.
Estimated  GFR eGFR Cr Age  if  fema () . (
.. =× × ×
−− 194 0 739
1 094 0 287 l le)
Figure 2 Relationship between eGFR with CRP. Mann-Whitney U-
test was used for comparison between median levels. Correlation was 
evaluated by Spearman's rank correlation method. Horizontal bars in-
dicate 10th, 25th, 50th (median), 75th, and 90th percentile levels. Ab-
breviations: r, correlation coefficient; eGFR, estimated glomerular 
filtration rate; CRP, C-reactive protein.
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Independent associations of eGFR with CRP
Because CRP and TRX showed significant correlations
with other clinical parameters, multiple regression mod-
els were employed to examine whether eGFR had signifi-
cant associations with CRP and TRX independent of
these possible confounders. As shown in Table 4, eGFR
showed an inverse association with CRP in model 1 in
which no adjustment was done. In model 2, the associa-
tion between eGFR and CRP was again significant after
adjustment for age and sex. In models 3 and 4, the associ-
ation between eGFR and CRP remained significant even
after further adjustment for smoking status or glucose
level. However, the association between eGFR and CRP
was not significant when adjusted for BMI, SBP, Non-
HDL-C, HDL-C, or TRX, in addition to age and sex.
Independent associations of eGFR with TRX
As shown in Table 5, eGFR showed an inverse association
with TRX in model 1 in which no adjustment was done.
In model 2, the association between eGFR and TRX was
again significant after adjustment for age and sex. In
models 3 through 8, the association between eGFR and
TRX remained significant even after further adjustment
for BMI, SBP, Non-HDL-C, HDL-C, smoking status, or
glucose. However, the association between eGFR and
TRX was not significant when adjusted for CRP in addi-
tion to age and sex.
Multiple regression models to simultaneously adjust for 
potential confounders
To further investigate the eGFR-CRP and the eGFR-TRX
links, we included all potential confounders simultane-
ously in multiple regression models (Table 6). CRP
showed significant and independent associations with
systolic BP (positively), non-HDL-C (positively), and
HDL-C (inversely), but not with eGFR (P = 0.16). TRX
showed a significant association with male sex, and trend
of association with eGFR (P = 0.06) and systolic BP (P =
0.08) at borderline significance.
Discussion
The aim of this study was to compare the levels of CRP
and TRX between subjects with normal and mildly
reduced renal function. When the subjects were divided
i n t o  t w o  g r o u p s  b y  e G F R ,  b o t h  C R P  a n d  T R X  w e r e
higher in the subjects with mildly reduced eGFR. Also,
eGFR showed significant inverse correlations with CRP
and TRX in the total subjects. The inverse associations of
eGFR with CRP and TRX remained significant after
adjustment for age and sex. When further adjustment
was done for 6 additional possible confounders, the
inverse associations of eGFR with CRP and TRX became
less significant. In such models, CRP was independently
associated with systolic BP, non-HDL-C, and HDL-C lev-
els. Also, TRX was associated with sex significantly, and
with eGFR and systolic BP at border significance. These
results suggest that the increased levels of CRP and TRX
in subjects with mildly reduced eGFR were mediated, at
least partly, by alterations in blood pressure and lipid lev-
els in mildly decreased kidney function.
Previous studies reported that patients with advanced
renal failure have increased levels of CRP and biomarkers
for oxidative stress including TBARS[14,15], phosphati-
dylcholine hydroperoxide[14], F2-isoprostane[31], and
AOPP[15]. However, there are only a few studies that
examined oxidative stress in those with mild reduction in
renal function. According to Witko-Sarsat et al[33],
plasma AOPP levels were increased early in the course of
CKD, and further increased in more advanced renal fail-
ure. Fortuno et al[34] showed that patients with stage 1-2
CKD had an increase in phagocytic NADPH oxidase-
dependent superoxide production in as compared with
healthy control subjects. Regarding antioxidant defense
Figure 3 Relationship between eGFR with TRX. Mann-Whitney U-
test was used for comparison between median levels. Correlation was 
evaluated by Spearman's rank correlation method. Horizontal bars in-
dicate 10th, 25th, 50th (median), 75th, and 90th percentile levels. Ab-
breviations: r, correlation coefficient; eGFR, estimated glomerular 
filtration rate; TRX, thioredoxin.
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in early CKD, Yilmaz et al[35] reported that erythrocytes
from patients with stage 1-2 CKD had lower activities of
SOD and glutathione peroxidase than healthy controls.
These previous studies suggested the increased oxidative
products and impaired antioxidant defense even in early
stages of CKD. However, no study examined possible
changes in the biomarkers for inflammation and oxida-
tive stress among subjects with mild reduction in eGFR as
compared to those with normal eGFR. In addition, these
previous studies did not made correction for possible
confounding variables, due presumably to small number
of subjects. The present study compared CRP and TRX
levels between those with normal and mildly reduced
eGFR, and showed that mild reduction in eGFR was asso-
ciated with increased levels of CRP and TRX in depen-
dent of age and sex using multivariate analyses in 182
subjects. These data provide further evidence supporting
the notion that inflammation and oxidative stress are
increased in a very early course of renal function loss.
In this study, eGFR, CRP, and TRX were correlated with
each other. Importantly, the association of eGFR and CRP
was not significant after adjustment for TRX in addition
to age and sex. Similarly, the association of eGFR and
TRX was not significant after adjustment for CRP in
addition to age and sex. These results suggest the close
association among inflammation, oxidative stress, and
renal function. Subjects with early stages of CKD have
increased NADPH oxidase activity[34] and compromised
antioxidant defense mechanisms[35]. These data may
indicate that impaired renal function is the cause of
increased oxidative stress. Conversely, since increased
oxidative stress causes organ damage, the increased oxi-
dative stress due to reduced GFR could, in turn, further
impair kidney function [38]. In addition, inflammation
may increase oxidative stress[15,31,39,40], and also pro-
mote loss of kidney function [41]. Furthermore, renal
insufficiency results in sustained inflammation, since
some inflammatory cytokines are excreted through kid-
neys[42]. Thus, these studies suggest the complex inter-
relationship among decreased renal function, increased
oxidative stress, and inflammation.
Furthermore, the present study indicates possible con-
tributions of blood pressure and plasma lipids to the
eGFR-CRP link and the eGFR-TRX link. In the fully-
adjusted models, eGFR was not significantly associated
with either CRP or TRX, whereas CRP was significantly
associated with systolic BP, HDL-C, and non-HDL-C lev-
els. TRX was associated with systolic BP at borderline sig-
nificance. Since both blood pressure and plasma lipids are
adversely affected by impaired kidney function, and these
are well known risk factors for atherosclerosis, we specu-
late that the increased levels of CRP and TRX in subjects
with mildly reduced eGFR were mediated, at least partly,
by alterations in blood pressure, plasma lipids and pre-
sumably arterial wall in such subjects.
We interpret the increased TRX levels associated with
mildly reduced eGFR to indicate that oxidative stress is
increased in those with mildly reduced renal function.
However, we cannot exclude other possibilities. The
increased TRX may be due simply to retention of TRX in
decreased renal function. So far, it is unknown to what
extent glomerular filtration is involved in the elimination
o f  T R X  f r o m  t h e  c i r c u l a t i o n .  A c c o r d i n g  t o  K a s u n o  e t
Table 2: Univariate correlation of CRP and TRX with various 
clinical parameters
Independent 
variables
Dependent variables
CRP TRX
eGFR -0.254*** -0.196**
Age 0.307*** 0.165*
Sex 0.199** 0.298***
BMI 0.377*** 0.188*
Systolic BP 0.316*** 0.219**
Non-HDL-C 0.300*** 0.059
HDL-C -0.381*** -0.177*
Smoking 0.154* 0.246**
Glucose 0.239** 0.113
TRX 0.335*** ---
The table gives Spearman's correlation coefficients with level of 
significance. Dummy variables were used for sex (1 for male, 0 for 
female) and smoking (1 for smokers, 0 for non-smokers). *P < 0.05, 
**P < 0.01, ***P < 0.001. See the footnote of Table 1 for 
abbreviations.
Table 3: Univariate correlation of eGFR with various clinical 
variables
Independent variables Correlation coefficient
Age -0.591***
Sex 0.269***
BMI -0.149*
Systolic BP -0.334***
Non-HDL-C -0.227**
HDL-C 0.074
Smoking 0.234**
Glucose -0.118
The table gives Spearman's correlation coefficients with level of 
significance. Dummy variables were used for sex (1 for male, 0 for 
female) and smoking (1 for smokers, 0 for non-smokers). *P < 
0.05, **P < 0.01, ***P < 0.001. See the footnote of Table 1 for 
abbreviations.Tsuchikura et al. BMC Nephrology 2010, 11:7
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al[18], TRX is detectable in urine of healthy individuals,
and urinary TRX is increased in some kidney diseases.
They also demonstrated the translocation of TRX from
renal tubular cells into urinary lumen in response to isch-
emia/reperfusion in mice. Thus, urinary TRX may repre-
sent 'leak' of TRX from damaged kidney cells rather than
glomerular filtration of the protein.
This study has several limitations. First, GFR was not
directly determined but estimated by the formula that
was developed for and validated in Japanese subjects.
Therefore, direct GFR determination would be needed to
obtain more solid conclusion. Second, because of the
cross-sectional design of this study, the associations
between parameters did not necessarily indicate causal-
ity. Prospective studies will be required for this purpose.
Third, the subjects of this study do not represent the gen-
eral population although we recruited them from the par-
ticipants of a health check-up program. They included
more women than men, and did not include those taking
medications for the three common diseases.
Table 6: Multiple regression analyses simultaneously including all potential confounding variables
Independent variables Dependent variables
CRP TRX
eGFR -0.114 -0.168
Age 0.080 0.046
Sex 0.040 0.208*
Smoking 0.094 0.123
Glucose 0.007 -0.094
BMI 0.125 0.085
Systolic BP 0.164* 0.145*
Non-HDL-C 0.158* -0.025
HDL-C -0.200* -0.017
R2 0.305*** 0.164***
The table gives beta coefficients between eGFR and CRP and between eGFR and TRX, and coefficients of determination (R2) for whole models. 
CRP and TRX were log-transformed to fit the linear models. Dummy variables were used for sex (1 for male, 0 for female) and smoking (1 for 
smokers, 0 for non-smokers). See the footnote of Table 1 for abbreviations.
*P < 0.05, ***P < 0.001.
Table 4: Independent association of eGFR with CRP in multiple regression models.
Model Covariables Beta coefficients for eGFR R2
1 unadjusted -0.265*** 0.07***
2 Age, sex -0.171* 0.158***
3 Model 2 + Smoking 0.240** 0.171***
4 Model 2 + Glucose -0.169* 0.168***
5 Model 2 + BMI -0.133 0.22***
6 Model 2 + SBP -0.160 0.179***
7 Model 2 + Non-HDL-C -0.151 0.216***
8 Model 2 + HDL-C -0.153 0.238***
9 Model 2 + TRX -0.123 0.208***
The table gives beta coefficients between eGFR and CRP, and coefficients of determination (R2) for whole models. CRP and TRX were log-
transformed to fit the linear models. Dummy variables were used for sex (1 for male, 0 for female) and smoking (1 for smokers, 0 for non-
smokers).
*P < 0.05, **P < 0.01, ***P < 0.001. See the footnote of Table 1 for abbreviations.Tsuchikura et al. BMC Nephrology 2010, 11:7
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Conclusions
In conclusion, subjects with mildly decreased eGFR
showed increased levels of biomarkers for inflammation
and oxidative stress. This finding is of clinical impor-
tance, since CKD is recognized as a very high-risk popu-
lation for CVD. Further studies are necessary whether the
observed deviations in the biomarkers of inflammation
and oxidative stress are predictive of occurrence of CVD.
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